Sign in Sign up for free

Volpara Health Technologies FCF yield

What is the FCF yield of Volpara Health Technologies?

The FCF yield of Volpara Health Technologies Limited is 2.01%

What is the definition of FCF yield?



Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.

ttm (trailing twelve months)

Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.

Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:

Free cash flow yield = Free cash flow per share / market price per share

FCF yield of companies in the Health Care sector on ASX compared to Volpara Health Technologies

What does Volpara Health Technologies do?

Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry worldwide. The company offers Volpara Analytics software, a cloud-based breast imaging analytics platform that delivers performance monitoring solutions; Volpara Live, which provides radiographers instant patient-based image quality feedback; Volpara Lung, a patient management software; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses Tyrer-Cuzick v8 Risk Evaluation Tool to calculate patients' risk of developing breast cancer; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. Volpara Health Technologies Limited has a strategic relationship with RevealDx to enhance lung screening capabilities. The company was formerly known as Matakina Technology Ltd. and changed its name to Volpara Health Technologies Limited in October 2015. Volpara Health Technologies Limited was incorporated in 2009 and is headquartered in Wellington, New Zealand.

Companies with fcf yield similar to Volpara Health Technologies